Global Hepatitis C Drug Pipeline Landscape Report 2021 Featuring 70+ Players – ResearchAndMarkets.com

Global Hepatitis C Drug Pipeline Landscape Report 2021 Featuring 70+ Players – ResearchAndMarkets.com




Global Hepatitis C Drug Pipeline Landscape Report 2021 Featuring 70+ Players – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hepatitis C (Infectious Disease) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.

Hepatitis C – Drugs In Development, 2021, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.

Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications.

The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting. The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

Report Highlights

Hepatitis C – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies / Universities / Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 13, 9, 15, 33, 23 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 13 and 17 molecules, respectively.

Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease).

Key Topics Covered:

  • Introduction
  • Hepatitis C – Overview
  • Hepatitis C – Therapeutics Development
  • Hepatitis C – Therapeutics Assessment
  • Hepatitis C – Companies Involved in Therapeutics Development
  • Hepatitis C – Drug Profiles
  • Hepatitis C – Dormant Projects
  • Hepatitis C – Discontinued Products
  • Hepatitis C – Product Development Milestones
  • Appendix

Companies Mentioned

  • AB Pharma Ltd
  • AbbVie Inc
  • Akshaya Bio Inc
  • Alla Chem LLC
  • Ascletis Pharma Inc
  • Atea Pharmaceuticals Inc
  • Auro Vaccines LLC
  • Beijing Kawin Technology Share-Holding Co Ltd
  • Beta Pharma Inc
  • Biotest Pharmaceuticals Corp
  • Biotron Ltd
  • Bolder Biotechnology Inc
  • Chia Tai Tianqing Pharmaceutical Group Co Ltd
  • Cocrystal Pharma Inc
  • Combioxin SA
  • ConserV Bioscience Ltd
  • Cytocom Inc
  • DEKK-TEC Inc
  • Dongguan HEC TaiGen Biopharmaceuticals Co Ltd
  • Ena Therapeutics Pty Ltd
  • Ennaid Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • FortuneRock (China) Ltd
  • Galactica Biotech Ltd
  • GeneCure Biotechnologies LLC
  • GeneOne Life Science Inc
  • Genoscience Pharma
  • Gilead Sciences Inc
  • Ginkgo Tree Pharmaceutical (Suzhou) Co Ltd
  • GlaxoSmithKline Plc
  • HEC Pharma Co Ltd
  • Hepion Pharmaceuticals Inc
  • ImmunoBiology Ltd
  • Inovio Pharmaceuticals Inc
  • Integrated BioTherapeutics Inc
  • iQur Ltd
  • J2H Biotech
  • Maxwell Biosciences Inc
  • Medivir AB
  • Merck & Co Inc
  • MetalloPharm LLC
  • Microbio Co Ltd
  • Nanjing Sanhome Pharmaceutical Co Ltd
  • Nanogen Biopharmaceutical Co
  • Novalex Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Orgenesis Inc
  • Palisades Therapeutics
  • PharmaEssentia Corp
  • Presidio Pharmaceuticals Inc
  • Regulus Therapeutics Inc
  • Riboscience LLC
  • Rodos BioTarget GmbH
  • Savoy Pharmaceuticals Inc
  • Shanghai Newsummit Biopharma Co Ltd
  • Shanghai Tangrun Pharmaceuticals Co Ltd
  • Shionogi & Co Ltd
  • Sino Biopharmaceutical Ltd
  • Sudershan Biotech Ltd
  • TaiGen Biotechnology Co Ltd
  • Tetranov International Inc
  • Therapure Biopharma Inc
  • THEVAX Genetics Vaccine USA Inc
  • Toray Industries Inc
  • Trek Therapeutics PBC
  • UBI Pharma Inc
  • Uvax Bio LLC
  • Vanworld Pharmaceutical (Rugao) Company Ltd
  • Vertex Pharmaceuticals Inc
  • Virocovax
  • Zylacta Corp

For more information about this report visit https://www.researchandmarkets.com/r/q0baya

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900